Sector News

Flagship snaps up Merck CMO

July 14, 2016
Life sciences

Flagship Ventures has created a new spot for former Merck EVP and CMO Dr. Michael Rosenblatt, benefiting from the R&D reorg at the pharma. He is joining the venture firm as CMO. Flagship is creating the position with Rosenblatt’s hire.

He has been a Merck exec since 2009; prior to that he held various positions including dean of Tufts University School of Medicine, a professor at Harvard Medical School, president of Beth Israel Deaconess Medical Center and director of the Harvard-MIT Division of Health Sciences and Technology.

“As Merck’s first Chief Medical Officer, Mike was a strong advocate for patients’ well-being, and we’re delighted to have him bring his deep experience and creativity to the Flagship community,” said Flagship founder and CEO Noubar Afeyan in a statement.

He added, “As Flagship’s CMO, he will play a key role in our partnerships with academic researchers and biopharmaceutical partners, and will support and guide Flagship companies as they conduct clinical research at a rapidly increasing scale.”

Rosenblatt is already on the board of Flagship portfolio company Rubius Therapeutics, which he joined in 2015. Flagship launched Rubius late last year with a $25 million investment to back the development of functionalized red blood cells to treat autoimmune conditions, metabolic diseases, cancer and other diseases.

“The fundamental technological and scientific breakthroughs at the heart of Flagship’s entrepreneurial innovations have to deliver real value to the patients who take the resulting drugs and the societies who pay for them, and I look forward to helping to bring that perspective as early as possible to the discovery, development, regulatory review and post-approval world,” said Rosenblatt.

By Stacy Lawrence

Source: Fierce Biotech

comments closed

Related News

January 29, 2023

Colorcon, Inc. signs Put agreement with intent to acquire controlled atmosphere packaging specialist Airnov Healthcare Packaging

Life sciences

Airnov provides critical healthcare industries with high-quality, controlled atmosphere packaging, to protect their products from moisture and oxygen. The business has manufacturing facilities in the USA, France, China and India and employs around 700 people.

January 29, 2023

Takeda pledges up to $1.13B for rights to Hutchmed’s cancer drug fruquintinib outside of China

Life sciences

Takeda of Japan has partnered with Hong Kong-based Hutchmed, gaining the commercial rights to colorectal cancer drug fruquintinib outside of China for $400 million up front, plus $730 million in potential milestone payments. Takeda also will help develop fruquintinib, which can be applied to subtypes of refractory metastatic colorectal cancer, regardless of biomarker status, the companies said.

January 29, 2023

Vir taps Bayer dealmaker Marianne De Backer as its next CEO

Life sciences

On April 3, Scangos, who’s been chief executive officer at Vir since the start of 2017, will hand over the reins to Marianne De Backer, Ph.D. De Backer comes over from Bayer, where she currently heads up pharmaceutical strategy, business development and licensing. Alongside her CEO appointment, De Backer is set to join Vir’s board of directors, the company said Wednesday.

How can we help you?

We're easy to reach